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In the infrainguinal position, the primary paten- 
cy of synthetic vascular grafts lies between 30% and 
55%. 1-3 This disappointing outcome is opposed by a 
5-year primary patency of approximately 70% for 
saphenous vein grafts in a comparable patient 
group3 As a consequence, ndothelial seeding has 
been introduced with the goal to reduce the surface 
thrombogenicity of the prosthetic material through 
the creation of an autologous endothelial coverage. 
First attempts were based on a single-staged tech- 
nique, where freshly harvested venous endothelial 
cells were seeded. In clinical trials, however, single- 
staged seeding failed, most likely because of the low 
number of available ndothelial cells and the result- 
ing insufficient endothelial cell inoculum. 4 
In the 1980s two alternative techniques were 
developed that addressed this shortcoming: 
endothelial cell sodding 5 and in vitro endothelializa- 
tion. 6 While sodding exploits the abundance of 
microvascular endothelial cells in adipose fat tissue, 
in vitro lining achieves a similar goal through mass 
culture of venous endothelial cells. Our group has 
been involved with in vitro lining over the past 15 
years. 6-11 The present report summarizes almost 11 
years of clinical experience with close to 140 patients 
and describes our efforts to enhance graft perfor- 
mance in current clinical studies. 
Patients and methods 
With the clinical introduction of a new and tmtest- 
ed surgical treatment for peripheral rtery disease, our 
human trials had to be guided by three principle con- 
siderations: First, wc had to initially assume that vein 
grafts are superior to endothelialized ePTFE grafts 
before proved otherwise. Therefore, the study was 
confined to patients who had no venous conduit avail- 
able. Second, the standards established by Rutherford 
for studies involving new methods in vascular surgery 
required that only a limited number of patients be ini- 
tially randomized. We restricted the randomization of
the first phase of our study to less than 50 patients. 
The third determinant for the design of the study was 
the fact that autologous endothelial lining involves a 
time-dependent i  vitro procedure. Thus, our study 
was naturally restricted to patients with subacute or 
chronic peripheral occlusive disease. 
When the 3-year follow-up of the randomized 
phase 1 of our trial, as well as a similar study from 
another center, showed significantly better esults in 
the endothelialized group than in the control 
group, ethical considerations determined phase 2. 
Since the withholding of the treatment from 
patients with no saphenous vein available would not 
have been justified against he background of the 
phase 1 results, we decided to offer the treatment as 
a routine procedure to all nonacute patients who 
relied on ePTFE prostheses. Eventually, after 10 
years of clinical phase 1 and 2 trials including 152 in 
vitro endothelialized ePTFE grafts, it became safe 
to conclude that in vitro endothelialized ePTFE 
grafts perform similarly to autologous vein grafts. 
As a result, phase 3 of the study was initiated as a 
European multicenter study in which endothelial- 
ized ePTFE grafts are being compared with saphe- 
nous vein grafts in thc challenging below-knee posi- 
tion. Prior to the commencement of this random- 
ized multicenter study, we aimed at the further 
improvement of the shear stress resistance of the 
lined endothelium through the use of an RGD- 
enriched, engineered fibrin matrix as a precoating 
substrate. 
Phase 1 
From mid 1989 and onward, 49 patients were 
randomized. Details of this study were previously 
reported. 9 Indications for surgery were disabling 
claudication in 37 patients (grade I chronic limb 
ischemia) and chronic limb ischemia in 12 patients 
(grade II in six patients and grade III in six patients). 
For endothelial cell harvest, the right external jugu- 
lar vein was taken under local anesthesia. Mass cul- 
ture of first-passage endothelial cells was performed 
with first-passage endothelial cells until the required 
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cell number of16 x 106 endothelial cells was con- 
firmed by in situ counting. Reinforced 6-mm ePTFE 
grafts (W.L. Gore, Flagstaff, Ariz) were precoated 
with clinically approved, fibrinolytically inhibited 
fibrin glue (Immuno, Vienna, Austria) and were fur- 
ther coated with human fibronectin (28 gg/mL). 
Seeding of endothelial cells onto the graft surface 
(8.1 + 4.2 x 105 EC/mL cell suspension) was done 
in an automated, temperature- and pH-controlled 
rotation device (Microplan, Vienna, Austria).6, ll
Subsequently, grafts were incubated for anothe~ 
11.6 + 3.0 days to allow the maturation of the 
cytoskeleton. Follow-up studies were performed 
after 9 days, 3 months, 6 months, and 1 year; they 
were performed on an annual basis thereafter. 
Patency was determined by the ankle/brachial index 
(ABI) and duplex sonography at each time interval. 
Angiography was performed annually and in patients 
with suspected graft occlusion. Graft occlusion was 
suspected if a deterioration of the clinical status of 
the limb was confirmed by a significant drop in the 
ABI or a lack of flow signal on duplex sonography. 
Only primary graft patency was considered. During 
the entire observation period, none of the patients 
were lost to follow-up. Eight patients in the control 
group and 10 patients in the endothelialized group 
died during follow-up for reasons other than periph- 
eral vascular problems. 
Phase 2 
After June 1993, in vitro endothelialization was 
offered to all patients undergoing bypass operations 
for peripheral arterial occlusion who were lacldng a 
suitable saphenous vein. One hundred twelve 
patients received 125 successfully endothelialized 
ePTFE grafts; in 13 of these patients an endothelial- 
ized prosthesis was bilaterally implanted. One hun- 
dred two graft implantations were done for clinical 
grade I ischemia (76 above knee, 26 below knee), 13 
for grade I1 (9 above knee, 4 below knee), and 10 
for grade III (6 above knee, 4 below knee). Because 
of the unavailability of human fibronectin for clinical 
use during phase 2, neither culture v ssels nor grafts 
could be preincubated with it. ABIs and duplex 
sonography were performed at 1 month, 3 months, 
6 months, and 1 year; from then onward, they were 
performed on an annual basis or at any deterioration 
of the clinical status. Angiography was only done 
after I year and on suspicion of graft occlusion. No 
patient was lost to follow-up, and 11 patients died of 
unrelated causes. 
Statistical analysis of the 78-month follow-up of 
our randomized trial (mean observation period 60 
months) and the 72-month follow-up of the subse- 
quent routine clinical implantation of endothelial- 
ized grafts (mean observation period 20 months) 
was performed with STATISTICA (StatSoft, USA) 
software using the Kaplan-Meier survivorship func- 
tion for survival analysis and the log-rank test and 
Gehan's Wilcoxon group comparison. 
Phase 3 
1. Improvement of precoating substrate: First- or 
second-passage adult venous endothelial cells 
were confluently seeded onto 15-cm long pre- 
coated ePTFE vascular grafts as described else- 
where. Precoating was done either with the stan- 
dard conventional fibrin matrix also used in phase 
1 and 2 of the clinical study or with an engineered 
fibrin that used the factor XIII cross-linldng 
process for the inclusion of RGD peptide into the 
matrix (3.5 mg/mL fibrinogen stock solution; 
Tisseal; Baxter/Immuno, Austria)) 2After seed- 
ing, grafts were postcultivated for another 9 days 
to allow the maturation of the cytoskeleton. 
Subsequently, endothelialized graft segments were 
placed into a perfusion loop that emulates the pul- 
satile flow patterns and shear forces of femoral 
arteries while sustaining physiologic metabolic 
conditions for the cells) 3 Four endothelialized 
grafts in cach group were exposed to such shear 
stress conditions for 24 hours. Samples were ana- 
lyzed by electron microscopy, histology, and vital 
epifluorescence microscopy before and after shear 
stress exposure. Epifluorescence images were dig- 
itized with a Coolpix 950 digital camera (Nikon, 
Japan) attached to the microscope. Digital micro- 
graphs were then analyzed with Photoshop 
(Adobe, USA) software, allowing the computation 
of the percentage of cell loss. Thrombogenicity 
studies and a preclinical confirmation of the in 
vitro experiments are currently under way in the 
nonhuman primate model. 
2. European Multicenter Study. Applications to the 
institutional ethics committees either have been 
approved or are currently under review. Each cen- 
ter has a randomization protocol for initially 100 
patients, comparing endothelial-lined ePTFE 
grafts with saphenous vein grafts in the below- 
knee position. 
Results and discussion 
The 152 grafts reported in both phase 1 and 2 of 
our clinical study represent the same ratio of above- 
versus below-knee grafts as the vast majority of stud- 
ies reported in the literature. As far as clinical stag- 
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ing is concerned, the literature is inconclusive. 
Although often implied that the prognosis of  stage 
I I I  patients is worse than of  stage I patients, practi- 
cally all large multicenter studies did not distinguish 
between clinical stages. 11 However, if one compares 
ePTFE studies, in which most patients were in stage 
I I I  with others that only investigated stage I 
patients, it seems as if the average 5-year patency of 
ePTFE prostheses lies in the mid-50% range for 
stage I patients and in the upper 40% range for stage 
I I I  patients, ll Moreover, most of  these studies were 
done in patients in which a vein graft was theoreti- 
cally obtainable. In a group that--similar to ours- -  
had no vein graft available, Veith et al 1 reported a 5- 
year patency of 29% for ePTFE prostheses 
In our phase 1 randomized trial, the Kaplan- 
Meier survivorship analysis howed a primary 3-year 
patency rate of  84.7% for endothelialized grafts and 
55.4% for control grafts. After 5 years it was 73.8% 
for the endothelialized group and 20.8% for the con- 
trois. After 9 years, the primary patency rate for 
endothelialized grafts remained high at 65%. 
Performance differences between the two groups 
were statistically significant (log-rank test; P = 
.00098 and Wilcoxon test; P = .0025). 
The subsequent phase 2 routine clinical implanta- 
tion of endothelialized ePTFE grafts showed a 6-year 
primary patency rate of 64.4% for all femoropopliteal 
reconstructions. The 90 grafts implanted in above- 
the-knee position during phase 2 had a 5-year paten- 
cy of 62.0%, which compares well with Veith's 70% for 
above-the-knee saphenous vein grafts. The 3-year pri- 
mary patency rate for our 35 endothelialized below- 
the-knee grafts was 78% comparable with the 80% 
that Veith et al reported for vein grafts in this position. 
The reversal of the normal patency pattern of ePTFE 
grafts with better results in the above-knee group is 
hypothesized to be due to a higher cell loss in this 
higher runoff and thus higher shear force group. 
As a solution, an RGD-enriched fibrin matrix was 
tested at the onset of phase 3. In grafts precoated with 
the conventional fibrin formulation, cell loss in vitro 
was 37.7% + 10.9%, corresponding with previous 
results. In contrast, cell loss was only 12.7% _+ 12.0% in 
grafts precoated with the engineered, RGD-enriched 
fibrin matrix (_P < .0001). Moreover, grafts precoated 
with the conventional fibrin manfix were also less con- 
fluently endothelialized (93.2% _+ 5.2%) after 9 days of 
incubation than grafts coated with the fibrin containing 
additional RGD peptides (97.2% _+ 2.8%; P = .025). 
In summary, our patency results for ePTFE grafts 
that were lined in vitro with autologous endothelial 
cells were distinctly better than both our control 
grafts and the patencies reported for untreated 
ePTFE grafts in the literature. Furthermore, it 
appears as if in vitro endothelialization achieves an 
approximation of the patency ofePTFE grafts to that 
of vein grafts. In this regard our patencies of 85%, 
74%, and 66% after 3, 5, and 9 years in phase I and 
73% and 68% after 3 and 5 years in phase 2 compare 
well with the 3- and 5-year patencies of 75% and 68% 
for vein grafts in Veith's multicenter study. 1 The 
overall slightly higher patency rate for our in vitro 
lined grafts may be explained with the higher pro- 
portion of stage I I  and I I I  patients in Veith's study. 
These results, together with an improved immediate 
cell retention on the engineered fibrin matrix, make 
it highly likely that the recently initiated multicenter 
study will eventually show a higher patency rate for 
the tissue-engineered PTFE grafts than for vein 
grafts, even in the challenging below-knee position. 
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The blood vessel is a structure of extraordinary 
sophistication. The physical continuity of vascular 
cells and tissues that make up the blood vessel wall 
contribute to its structural integrity while also 
maintaining homeostasis through biochemical regula- 
tion. The endothelial monolayer that lines the 
normal blood vessel serves as a twofold regulator of 
vascular physiology. The endothelium provides truc- 
tural integrity to the blood vessel by forming a con- 
tinuous, selectively permeable, thromboresistant bar- 
tier between drcnlating blood and the arterial wall. At 
the same time, it also produces and supplies products 
that control blood flow, vessel tone, thrombosis, 
platelet activation, adhesion, aggregation, leukocyte 
adhesion, monocyte infiltration, and smooth muscle 
cell migration and proliferation. Endothelial injury, 
such as occurs after angioplasty, not only removes the 
physical barrier but also interferes with the biochemi- 
cal regulatory potential of the blood vessel and sets 
into motion a sequence of events that leads to the 
proliferation and migration of smooth muscle cells 
resulting in obstructive arterial lesions. This process of 
restenosis leads to critical narrowings in significant 
numbers of patients after angioplasty, bypass grafting, 
and organ transplantation. 
Tissue engineering enables the development of 
biological substitutes that restore, maintain, or 
improve tissue function 1while also providing sub- 
strates by which to examine structure-function rela- 
tionsbips for specific tissues or organs. Cells may be 
implanted at sites distant or in different configurations 
from their original state, enabling examination of any 
added potential benefit of cell secretory function to 
regulation of tissue biology above that imposed by 
preservation ftissue architecture alone. This might be 
especially important in vascular biology where the 
autocrine, paracrine, and endocrine function of the 
endothelium is rapidly emerging. Innovative studies 
have attempted to recreate the structure of the blood 
vessel by autologous endothelial cell transplantation, 
implantation of endothelial cell-seeded interposition 
grafts, or endovascular stents. 2-6 Yet, the question 
remains as to whether eestablishing biochemical con- 
trol ofvascnlar homeostasis also requires reestablishing 
the ordered architecture of the blood vessel. We have 
demonstrated, through the use of tissue-engineered 
endothelial cells, that the biologic effect of these cells 
on blood vessel regulation is maintained even when 
they are implanted at a distance from the lumen. 
Engrafted endothelial cells on three-dimensional po y- 
mer matrices, implanted in the perivascular space of 
injured rat carotid arteries, reduced intimal thickening 
by 88%. 7 In contrast, he isolated infusion f heparin, 
an endothelial cell product analog and potent smooth 
muscle cell inhibitor, only reduced intimal hyperplasia 
by 30%. These experiments supported the hypotheses 
that endothelial control over vascular repair is derived 
from the sum of a number of secreted endothelial 
cell-based products and need not emanate from the 
luminal surface. 8 
We recently addressed two important questions 
relating to the biologic effects of perivascular 
endothelial cell implantation. First, we examined 
whether allotransplantation f endothelial cell grafts 
was effective in controlling vascular repair in a 
porcine carotid artery model of vascular injury, 
thought o be less responsive to growth-regulatory 
agents than simpler animal models. Second, we 
explored whether xenotransplantation, a central issue 
in developing safe and practical clinical strategies, was 
more or less effective than allotransplantatlon. We 
now report that perivascular tissue-engineered 
endothelial cell implants exert profound control over 
intimal growth after arterial injury in pigs. 
Furthermore, despite an increased immtme response 
to cross-species transplantation, beneficial control of 
vascular repair was maintained. These results provide 
insight into how the endothellum controls vascular 
homeostasis and are a further step toward the devel- 
opment of clinically viable strategies for modulating 
vascular epair after injury. Further exploration of 
how tissue-engineered endothelial cell grafts control 
vascular repair, particularly in settings of more chron- 
ic vascular injury, will afford insight into the structure 
and function of the blood vessel wall and into how 
experimentally effective techniques may be brought 
to clinical fruition. 
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